目次

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Spinocerebellar Ataxia (SCA) - Overview
Spinocerebellar Ataxia (SCA) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Spinocerebellar Ataxia (SCA) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Spinocerebellar Ataxia (SCA) - Companies Involved in Therapeutics Development
Spinocerebellar Ataxia (SCA) - Drug Profiles
Spinocerebellar Ataxia (SCA) - Dormant Projects
Spinocerebellar Ataxia (SCA) - Discontinued Products
Spinocerebellar Ataxia (SCA) - Product Development Milestones
Featured News & Press Releases
May 23, 2022: Biohaven provides update on phase 3 clinical trial evaluating troriluzole for spinocerebellar ataxia (SCA)
Nov 08, 2021: Seelos Therapeutics announces FDA acceptance of investigational new drug application and grant of fast track designation for SLS-005 (IV Trehalose) for the treatment of Spinocerebellar Ataxia
Oct 07, 2021: Blade Therapeutics announces publication of preclinical evidence supporting neuroprotective effects of proprietary calpain inhibitor in a rare inherited neurodegenerative disease
Jun 29, 2021: US FDA grants VICO therapeutics orphan-drug designation for VO659, an investigational therapy for spinocerebellar ataxia
Apr 13, 2021: Biohaven announces presentations on troriluzole at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting
Mar 29, 2021: SM Life Sciences submits IND for spinal cerebellar ataxia treatment
Feb 10, 2021: European Commission grants Vico Therapeutics Orphan Drug Designation for VO659, an investigational herapy for spinocerebellar ataxia
Dec 21, 2020: Seelos Therapeutics announces issuance of a patent for Trehalose (SLS-005) in Israel
Nov 11, 2020: Biohaven Pharmaceuticals inaugural partner Of National Ataxia Foundation's drug development collaborative
Jan 23, 2020: Cadent Therapeutics announces FDA acceptance of IND application for CAD-1883 for Spinocerebellar Ataxia (SCA)
Jan 22, 2020: Kissei announces the publication of the results of phase III clinical trials of rovatirelin for the treatment of spinocerebellar degeneration in the Journal of Neurology, Neurosurgery, and Psychiatry
Dec 04, 2019: Seelos Therapeutics receives notice of allowance for an additional US patent for Trehalose (SLS-005)
May 29, 2019: Cadent Therapeutics announces FDA Orphan Drug Designation for CAD-1883 for Spinocerebellar Ataxia
May 07, 2019: Biohaven advances late stage clinical program and novel targets from neuroinnovation platform
May 03, 2019: Biohaven announces presentation of Troriluzole in phase IIb/III trial at American Academy Of Neurology (AAN) 2019 Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Spinocerebellar Ataxia (SCA), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Anima Biotech Inc, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Annji Pharmaceutical Co Ltd, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Biogen Inc, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by BioXcel Corp, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Blade Therapeutics Inc, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Celavie Biosciences LLC, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Corestem Inc, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Dystrogen Therapeutics SA, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Enzerna Biosciences LLC, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Everfront Biotech Inc, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Exicure Inc, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Gene Therapy Research Institution Co Ltd, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by IntraBio Ltd, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Ionis Pharmaceuticals Inc, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Locanabio Inc, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Novartis AG, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by PTC Therapeutics Inc, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Q-State Biosciences Inc, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Sclnow Biotechnology Co Ltd, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Seelos Therapeutics, Inc., 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Shionogi & Co Ltd, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Steminent Biotherapeutics Inc, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Triplet Therapeutics Inc, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Vico Therapeutics BV, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Vybion Inc, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Wave Life Sciences Ltd, 2022
Spinocerebellar Ataxia (SCA) - Dormant Projects, 2022
Spinocerebellar Ataxia (SCA) - Discontinued Products, 2022

List of Figures
Number of Products under Development for Spinocerebellar Ataxia (SCA), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022